Aimmune Therapeutics Names Haumann to Board of Directors
5 November 2018 - - US-based biopharmaceutical company Aimmune Therapeutics, Inc. (NASDAQ: AIMT) has named Brett Haumann, M.B.B.Ch., M.B.A. to its board of directors, the company said.

Haumann's extensive biotech and pharmaceutical leadership experience includes more than 20 years of development and discovery work in allergy and pulmonary medicines.

Haumann is chief medical officer and senior vice president, clinical development, at Theravance Biopharma.

Prior to joining Theravance Inc. in 2013, Haumann served as chief medical officer of the UK allergy company Circassia Ltd.

He also spent more than a decade with GlaxoSmithKline, where, as vice president of clinical development, he was responsible for late-stage development of medicines for asthma and chronic obstructive pulmonary disease.

Haumann began his industry career with Glaxo Wellcome in the United Kingdom and South Africa, after working as an internal medicine practitioner and clinical researcher in South Africa.

Aimmune Therapeutics is a biopharmaceutical company developing treatments for life-threatening food allergies.

The company's Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens.

Aimmune's first investigational biologic product using CODIT, AR101 for the treatment of peanut allergy, has received the FDA's Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age.

The company plans to submit regulatory filings for marketing approval of AR101 in the United States and Europe based on data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in 4–17-year-old subjects met its primary and key secondary endpoints, and additional ongoing and completed AR101 clinical trials.